Skip to content
Screener

Perspective Therapeutics CATX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$20.96M-17,370%
Immunome logo
ImmunomeIMNM
-$73.46M-69.2%
uniQure logo
uniQureQURE
-$79.43M-85.5%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$45.85M-14.6%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
-$3.93M-49.7%
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$29.3M-21.7%
Net income-$26.8M-24.7%
EPS (diluted)-$0.22+24.1%

Balance sheet

See full
Cash & equivalents$48.5M+68.1%
Total debt$3.9M+11.1%
Total equity$323.9M+21.9%
Total assets$392.0M+26.2%

Cash flow

See full
Operating cash flow-$20.7M-3.5%
CapEx$14.2M+1,284%
Free cash flow-$34.8M-66.1%

Valuation

See full
Market cap$342.14M+25.3%
Enterprise value$297.56M+20.1%

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp

Returns & leverage

See full
Return on equity-39.5%+14.0pp
Debt / equity0.0×
Current ratio6.6×-8.5×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Perspective Therapeutics’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:34 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342512
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Basic and diluted loss per share:
Loss from continuing operations$(0.22)$(0.30)$(0.47)$(0.55)
Gain from discontinued operations-0.01-0.01
Basic and diluted loss per share$(0.22)$(0.29)$(0.47)$(0.54)
Weighted average number of shares used in computing net loss per share:
Basic and diluted120,65174,235112,17473,301
Unrealized gain (loss) on available-for-sale securities$5$(16)$(331)$54
Comprehensive loss$(26,781)$(21,501)$(53,306)$(39,608)

ITEM 1 - FINANCIAL STATEMENTS

FAQ

What is Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Perspective Therapeutics (CATX) reported comprehensive income (loss), net of tax, attributable to parent of -$26.78M in Q2 2026.
How has Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 24.6% year-over-year, from -$21.5M to -$26.78M.
What is the long-term trend for Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2023 to 2025), Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 48.8% compound annual growth rate (CAGR), from -$46.51M to -$102.96M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This represents the total change in equity during a period resulting from transactions and other events from non-owner sources, including both net income and other comprehensive income items. It provides a comprehensive view of the company's financial performance by incorporating unrealized gains or losses that are typically excluded from traditional net income. This metric is essential for understanding the total impact of all financial activities on the company's net worth.

Ask your AI about Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude